Shanghai Fosun Pharmaceutical (Group) Co., Ltd.SSE: 600196

Fosun Pharma Announces H-Share Repurchase Plan of Up to HK$ 1 Billion

· Issued by Shanghai Fosun Pharmaceutical (Group) Co., Ltd. via PR Newswire

Summary by 6ix AI

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) on September 6, 2026 set out a plan to repurchase its H-shares, its Hong Kong-listed shares, for an aggregate amount of up to HK$1 billion. Repurchased shares will be cancelled or held as treasury shares, meaning shares the company keeps itself.

Key details

  • The plan has come into effect and will be implemented as soon as practicable.
  • The repurchase will be primarily funded by proceeds from the disposal of approximately 6.00% equity interest in Gland Pharma, for total consideration of around US$294 million. Net proceeds from that transaction will primarily go to R&D investments, share repurchases and repayment of interest-bearing debts.
  • Upon completion of the Gland Pharma transaction, Fosun Pharma remains the promoter of Gland Pharma with an approximate 45.76% equity interest, and Gland Pharma will continue to be consolidated into Fosun Pharma's financial statements.
  • For the first half of 2026, revenue was RMB 20,442 million, up 4.75% year-on-year, and profit attributable to shareholders of the listed company, net of non-recurring gains and losses, was RMB 1,144 million, up 19.09% year-on-year.
  • Net cash generated from operating activities for the first half of 2026 was RMB 2,424 million, up 13.59% year-on-year.

What’s still pending

  • Repurchases will be evaluated and carried out on a rolling basis in response to market conditions, up to the HK$1 billion limit.
  • The Gland Pharma stake and consolidation figures apply upon completion of the disposal.

6ix AI wrote this summary from the release below and checked it against the release.

SHANGHAI, Sept. 6, 2026 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma", stock code: 600196.SH; 02196.HK) today announced an H-share repurchase plan, under which the company intends to repurchase its H-shares with an aggregate amount of up to HK$1 billion. The shares so repurchased will be cancelled or held as treasury shares. Taking concrete action to respond to market concerns, this repurchase plan demonstrates management's unwavering confidence in the company's intrinsic value. The plan has come into effect and will be implemented as soon as practicable. As a continuation of the Group's long-term value management toolkit, the company will dynamically evaluate and execute repurchases on a rolling basis in response to market conditions, establishing a normalized mechanism for shareholder returns.

In the first half of 2026, Fosun Pharma's earnings quality continued to improve, with revenue contributions from innovative drugs and international markets steadily increasing. Core operational indicators further consolidated upon the foundation of 2025:

  • Revenue: RMB 20,442 million, up 4.75% year-on-year;

  • Profit attributable to shareholders of the listed company, net of non-recurring gains and losses: RMB 1,144 million, up 19.09% year-on-year;

  • Net cash generated from operating activities: RMB 2,424 million, up 13.59% year-on-year.

The repurchase will be primarily funded by proceeds from the disposal of approximately 6.00% equity interest in Gland Pharma, with total consideration of around US$294 million. Upon completion of the transaction, Fosun Pharma remains the promoter of Gland Pharma with an approximate 45.76% equity interest, and Gland Pharma will continue to be consolidated into Fosun Pharma's financial statements. Net proceeds from the transaction will primarily be allocated toward the Company's R&D investments, share repurchases, and the repayment of interest-bearing debts. As the controlling shareholder, Fosun Pharma remains fully confident in Gland Pharma's long-term development and its enduring role as a key engine for overseas value creation.

Looking ahead, Fosun Pharma will stay focused on innovation and globalization, accelerating the R&D progress and commercialization of its major pipeline candidates. This repurchase program is intended to convey the Company's confidence in its intrinsic value and to generate sustainable returns for shareholders.

View original content:https://www.prnewswire.com/news-releases/fosun-pharma-announces-h-share-repurchase-plan-of-up-to-hk-1-billion-302870811.html

View original source (PR Newswire)Shanghai Fosun Pharmaceutical (Group) Co., Ltd. on 6ix

Earlier from Shanghai Fosun Pharmaceutical (Group)

Later from Shanghai Fosun Pharmaceutical (Group)

All Shanghai Fosun Pharmaceutical (Group) news releases